The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases
Disclosures: Sadatsugu Sakane: Nothing to Disclose, Hiroaki Fuji: Nothing to Disclose, Animesh Singh: Nothing to Disclose, Hyun Young Kim: Nothing to Disclose, Mojgan Hosseini: Nothing to Disclose, Yusuke Kimura: Nothing to Disclose, Raquel Weber: Nothing to Disclose, Wonseok Lee: Nothing to Disclose, Kanani Hokutan: Nothing to Disclose, Souradipta Ganguly: Nothing to Disclose, Karin Diggle: Nothing to Disclose, Xiao Liu: Nothing to Disclose, Debanjan Dhar: Nothing to Disclose, Linda Burkly Burkly: Editas Medicine: Employee, David Brenner: Nothing to Disclose, Tatiana Kisseleva: Nothing to Disclose 1990 PRECLINICAL PROOF OF CONCEPT OF SAFETY AND EFFICACY FOR RTX001, A NOVEL AUTOLOGOUS MACROPHAGE CELL THERAPY PRODUCT FOR END-STAGE LIVER DISEASE Moony Su 1 Olivia Matthews 1 Mark Cant 1 Anna Hoy 1 Niya Aleksieva 1 Rachel Lopera 1 Philip Starkey Lewis 1 Alejandro Armesilla-Diaz 1 Keith Sutton 1 Kayleigh Thirlwell 1 Lara Campana 1 , 1 Resolution Therapeutics Background: Patients with end-stage liver disease (ESLD) have extensive fibrosis and inflammation, which cause loss of organ function, resulting in decompensation events and limited life expectancy
CollagenAn important fish allergen for improved diagnosis[J]
Also, AC protected Hep3B liver cells in vitro from DEN-induced cytotoxicity, DNA damage, and reactive oxygen species (ROS) accumulation, while preventing mitochondrial membrane potential loss
